Mirapex (pramipexole) in the treatment of non-motor disturbances in Parkinson's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 108, Issue 5, 2008, Pages 32-38

  Nodel, M R ^a   Yakhno, N N ^a  

^a NONE

Author keywords

Anxiety; Depression; Mirapex; Non motor disturbances; Parkinson's disease; Sleep disorder

Indexed keywords

EID: 46949110775     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Russian source
9. Russian source
10. Russian source
11. Aiken C.B. Pramipexole in psychiatry: asystemic review of the literature. J Clin Psychiat 2007; 68: 1230-1236.
12. Arbor J.A., Wayne Martin W.R., Pogarell O. Tolerability and safety profile of pramipexole in the treatment of Parkinson's disease. Rev Contemp Pharmacother 2001; 12: 105-124.
13. Barone P., Scarzella L., Antonini A. et al. Pramipexole versus sertraline in the treatment of depression in Parkinsons disease. J Neurol 2005; 4: 1-7.
14. Bressman S.B., Shulman L.M., Tanner C.M. et al. Long-term safety and efficacy of pramipexole in early Parkinsons disease.Neurol 1999; 52: Suppl 2: 34.
15. Chaudhuri K.R. Nocturnal symptoms complex in PD and its management. Neurol 2003; 61: Suppl 3: 237-241.
16. Chaudhuri K.R., Pal S., Marco Di A. et al. The sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinsons disease. J Neurol Neurosurg Psychiat 2002; 73: 629-635.
17. Corrigan M. H., Denahan A.Q., Wright C. E. et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 2000; 11: 58-65.
18. Dooley M., Markham A. Prampexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging 1998; 12: 6: 495-514.
19. Eichhorn T.E., Schrag A., Trenkwalder C. et al. Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease. Nevrvenarzt 1995; 66: 12: 933-941.
20. Garcia-Borreguero D., Larrosa O., Bravo M. Parkinsons disease and sleep. Sleep Med Rev 2003; 7: 2: 115-129.
21. Goeti C.G., Poewe W., Rascol O. Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson's Disease: 2001 to 2004. Mov Dis 2005; 20: 5: 523-539.
22. Horstink M., Tolosa E., Bunuccelli U. et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part 1: early (noncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-1185.
23. Kulisevsky J., Avila A., Barbanoj M. et al. Acute effects of levodopa on neuropschological performance in stable and fluctuating Parkinsons disease patients at different levodopa plasma levels. Brain 1996; 119: 2121-2132.
24. Kulisevsky J., Garcia-Sanchez C., Berthier M.L. et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson disease: a two-year follow-up study of previously untreated patients. Mov Dis 2000; 15: 613-626.
25. Lemke M.P., Brecht U.M., Kassier J.K. et al. Anhedonia, depression, and motor functioning in Parkinsons disease during treatment with Pramipexole. J Neuropsych Clin Neurosci 2005; 17: 2: 214-220.
26. Lieberman A., Minagar A., Pinter M.M. The effect of pramipexole in the treatment of Parkinson's disease. Rev Contemp Pharmacother 2000; 12: 59-86.
27. MiyaSaki J.M., Martion W., Suchowersky O. et al. Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. Ncurol 2002; 58: 1: 11-17.
28. Moller J C. Oertel W.H., Koster J. et al. Long-term efficacy and safely of Pramipexolc in advanced Parkinsons disease: results from a European multiccntcr trial. Mov Dis 2005; 5: 602-610.
29. Parkinson Study Group, Kierburtz K. Safely and Efficacy of Pramipexole in Early Parkinson Disease: A Randomized Dose-Ranging Study. JAMA 1997; 278: 125-130.
30. Parkinson Study Group, Holloway K.G. Pramipexolc Versus Levodopa as Initial Treatment for Parkinson Disease: A 4-year Randomized Controlled Trial. Arch Neurol 2004; 61: 1044-1053.
31. Pinter M.M.. Pogarell O., Oertel W.H. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomized, multicentre study. J Neurol Neurosurg Psych 1999; 66: 436-441.
32. Pogarell O., Gasser T., Van Hilten J.J. et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiat 2002; 72: 1-7.
33. Rektorova I., Rektor I., Bares M. et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentrc prospective randomised study. Eur J Neurl 2003. 10: 399 406.
34. Saletu M., Anderer P., Saletu-Zyhlarz, G. et al. Acute placebo-controlshy; led sleep laboratory studies and clinical follow-up with pramipexolc in patients with restless legs syndrome. Cur Arch Psychiat Clin Neurosci 2002; 252: 185-194.
35. Scaravilli T., Gasparoli E. Rinaldi F. et al. Health related quality of life in Parkinsons disease. J Nourol Neurosurg Psychiat 2003; 74: 2: 163-169.
36. Schmidt M.H., Koshal V.B., Schmidt H.S. Use of pramipcxole in REM sleep behavior disorder: results from a case scries. Sleep Med 2006; 7: 418-423.
37. Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease. J Nourol Neurosurg Psychiat 2000; 69: 308-312.
38. Shannon K.M., Bennett J.P., Friedman J.H. et al. Efficacy of Prampexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurol 1997; 49: 724-728.
39. Szegedi A., Hillert A., Wetzel H. et al. Pramipexole, adopamine agonist, in major depression: antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol 1997; 20: Suppl 1: 36-45.